compound glp 1 news versions of GLP-1 drugs for weight loss halted by FDA Compounded GLP-1s: Why doctors worry

62 Another study that evaluated clinical outcomes in patients with diabetes, treated by cardiac resynchronization therapy with a defibrillator (CRT-d), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) in addition to conventional hypoglycemic therapy versus CRTd patients under conventional hypoglycemic drugs found that CRTd patients with diabetes treated by GLP-1 RA therapy versus CRTd patients with diabetes that did not receive GLP-1 RA therapy, experienced a significant reduction of NYHA class, associated to higher values of 6 minutes walking, and higher rate of CRTd responders

While Byetta is not a weight loss medication, participants lost an average of 6 to 6.4 pounds

Tell your health care professional if you feel your heart racing or pounding in your chest and it lasts for several minutes dehydration leading to kidney problems

Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data

Pricing is competitive with Fella

Tirzepatide actually shows lower discontinuation rates due to adverse events in clinical trials